Predictive methods, physicochemical measurements, and structure activity relationship studies suggest that corticotropin-releasing factor (CRF; corticoliberin), its family members, and competitive antagonists (resulting from N-terminal deletions) usually assume an a-helical conformation when interacting with the CRF receptor(s). To test this hypothesis further, we have scanned the whole sequence of the CRF antagonist Nle21'38]r/hCRF-(12-41) (r/hCRF, rat/human CRF; Nle, norleucine) with an i-(i + 3) bridge consisting of the Giu-Xaa-Xa:-Lys scaffold. We have found astressin {cyclo (30) (31) (32) (33) Nle2l,38,Glu30,Lys33] Corticotropin-releasing factor (CRF; corticoliberin) is a 41-residue peptide amide which stimulates the release of corticotropin (ACTH) (1, 2) and acts within the brain to mediate a wide range of stress responses (3). The actions of CRF are mediated through binding to CRF receptors, several of which have been characterized recently (4-10). These receptors, like those for growth hormone-releasing factor, calcitonin, and vasoactive intestinal peptide, are coupled via G proteins and have seven putative transmembrane domains. The actions of CRF can also be modulated by a 37-kDa CRF-binding protein (CRF-BP) (11). To probe the physiological role of CRF, we have developed competitive antagonists that are particularly potent when administered in the central nervous system; however, these same analogs bind pituitary receptors with lower affinity than does CRF, and their peripheral administration results in weak and short-lived effects in vivo (12). Synthetic CRF antagonists such as the a-helical CRF-(9-41)
[D-Phel2,Nle2l138]r/hCRF-(12-41), our present standard, and 300 times more potent than the corresponding linear analog in an in vitro pituitary cell culture assay. Astressin has low affinity for the CRF binding protein and high affinity (K1 = 2 nM) for the cloned pituitary receptor. Radioiodinated [D-1251-Tyrl2Jastressin was found to be a reliable ligand for binding assays. In vivo, astressin is significantly more potent than any previously tested antagonist in reducing hypophyseal corticotropin (ACTH) secretion in stressed or adrenalectomized rats. The cyclo (30) (31) (32) (33) [Ac-Pro4,D-Phe'2,Nle21,38,Glu30, Lys33]r/hCRF-(4-41) agonist and its linear analog are nearly equipotent, while the antagonist astressin and its linear form vary greatly in their potencies. This suggests that the lactam cyclization reinstates a structural constraint in the antagonists that is normally induced by the N terminus ofthe agonist.
Corticotropin-releasing factor (CRF; corticoliberin) is a 41-residue peptide amide which stimulates the release of corticotropin (ACTH) (1, 2) and acts within the brain to mediate a wide range of stress responses (3) . The actions of CRF are mediated through binding to CRF receptors, several of which have been characterized recently (4) (5) (6) (7) (8) (9) (10) . These receptors, like those for growth hormone-releasing factor, calcitonin, and vasoactive intestinal peptide, are coupled via G proteins and have seven putative transmembrane domains. The actions of CRF can also be modulated by a 37-kDa CRF-binding protein (CRF-BP) (11) . To probe the physiological role of CRF, we have developed competitive antagonists that are particularly potent when administered in the central nervous system; however, these same analogs bind pituitary receptors with lower affinity than does CRF, and their peripheral administration results in weak and short-lived effects in vivo (12) . Synthetic CRF antagonists such as the a-helical CRF-(9-41) (compound 2, Table 1 (12) . A recent NMR study of hCRF in 66% (vol/vol) aqueous trifluoroethanol identified a well-defined a-helix between residues 6 and 36, with an extended N terminus and a disordered C terminus (14) . The first half of the a-helix was clearly amphipathic, as recognized earlier from model studies (15, 16) . All experimental and theoretical data pointed to the fact that CRF-like molecules assume an a-helical conformation upon binding to their receptors; nevertheless, we were still faced with the challenge of devising and implementing strategies (conceptual as well as synthetic) that would allow us to lock the CRF structure in its bioactive conformation (hypothetically a-helical).
One means of achieving conformational stability is to create side-chain-to-side-chain covalent bonding that is not available to most biological systems. Salt bridges are known to stabilize tertiary structures in proteins, and examples can be found of i-(i + 3) and i-(i + 4) interactions (Glu or Asp to Lys or Arg or His). Such salt bridges can be replaced in some cases by a covalent amide bond forming a lactam ring in molecules like growth hormone-releasing factor (17, 18) and CRF (16) 
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. length, chirality, and positioning of the lactam bond led to the identification of cyclo (20) (21) (22) (23) [D-Phe12,Glu20,Lys23,Nle21'38]-hCRF-(12-41) as the most potent diastereomer (2.9 times the potency of compound 1). From these observations, we concluded that an i-(i + 3) Glu to Lys lactam bridge was compatible with a-helix stabilization and most likely was the best possible bridging moiety to fulfill our goal. To further test this hypothesis, we completed the synthesis of an i-(i + 3) bridge scan Glu-Xaa-Xaa-Lys of compound 1, which is one of the most potent CRF antagonists reported to date (12) .
MATERIALS AND METHODS Synthesis of CRF Analogs. All analogs shown in Table 1 were synthesized either manually or on a Beckman model 990 peptide synthesizer by using the solid-phase approach, a 4-methylbenzhydrylamine resin (16) and the tert-butoxycarbonyl (Boc) strategy with orthogonal protection [9-fluorenylmethoxycarbonyl (Fmoc) and 0-fluorenylmethyl (Ofm)] of the side chains of residues to be cyclized (17) . Amino acid derivatives Boc-Ala, Boc-Arg(Tos), Boc-Asn(Xan), Boc-Asp(cHex), BocGln(Xan), Boc-Glu(cHex), Boc-His(Tos), Boc-Ile, Boc-Met, Boc-Leu, Boc-Phe, Boc-Pro, Boc-Ser(Bzl), Boc-Thr(Bzl), BocTyr(2,6-Br2-Bzl), and Boc-Val were obtained from Bachem. Boc-Glu(Ofm) and Boc-Lys(Fmoc) were synthesized as described (19) . All solvents were reagent grade or better. The boc group was removed with 60% (vol/vol) trifluoroacetic acid (TFA) in dichloromethane (DCM) and 10% (vol/vol) ethanedithiol. Main-chain assembly was mediated by diisopropylcarbodiimide. Coupling time was 90-120 min followed by acetylation (excess acetic anhydride in DCM for 15 min). Three-fold excess protected amino acid was used based on the original substitution of the 4-methylbenzhydrylamine resin. Deprotection of the Fmoc group was achieved by using a solution of 20% (vol/vol) piperidine/80% dimethylformamide (DMF) (2 x 10 min) followed by sequential washes with DMF, MeOH, 10% (vol/vol) triethylamine/DCM and DCM. Lactam formation was mediated by using 0-(benzotriazol-1-yl)-N,N,N'-N'-tetramethyluronium tetrafluoroborate (TBTU) or 0-(benzotriazol-1-yl)-N,N,N',N',-tetramethyluronium hexafluorophosphate (HBTU) in DMF or N-methylpyrrolidone. Best results were obtained when the peptide chain was assembled in its entirety prior to cleavage of the Fmoc-and Ofm-protecting groups and cyclization as shown (16) . The peptides were cleaved and deprotected in HF and purified by using reversed-phase HPLC and two or three solvent systems (triethylammonium phosphate at pH 2.25 and/or 6.5 and 0.1% TFA) (20, 21) .
Characterization of CRF Analogs. Peptides were characterized as shown in Table 1 Circular Dichroism (CD) Spectra (see Fig. 1 ). CD spectra were obtained with a computer-controlled Aviv Associates (Lakewood, NJ) model 62DS spectropolarimeter under the control of the manufacturer's 60DS operating system. Spectra were collected at 1.0-nm intervals in the range of 190-250 nm as the average of four runs using a 2.0-sec integration time and a spectral bandwidth of 2.0 nm in 0.5-mm cuvettes thermostated at 20°C. Spectra were collected under two sets of buffer conditions: 0.02 M sodium phosphate, pH 6.5, and the same buffer diluted 1:1 (vol/vol) with 2,2,2-trifluoroethanol. Concentrations were determined on the basis of the calculated molecular mass of the TFA salt of the purified lyophilized peptide. Residue molar elipticities were calculated on the basis of the number of residues in each analog, irrespective of any side-chain bridging amide bonds.
In (24) . The Ki values listed in Table 1 were measured by using the cloned human CRF-RA1 (4, 24) stably expressed in CHO cells, as described (4) . Errors are the 95% confidence limits from three or more binding assays.
Effect of the Astressin (Compound 3) on ACTH Secretion in Adrenalectomized Rats (see Fig. 2 ). Adult male rats were adrenalectomized under halothane anesthesia 8 days prior to the experiments. Their diet was supplemented with oranges, and their water contained 0.9% NaCl. They were equipped with indwelling jugular cannulae (25) Fig. 3 ). Intact male rats were equipped with indwelling jugular cannulae (25) . On the day of the assay, rats were placed in individual boxes, and mild electroshocks (1 mA, 1-sec duration, 2 shocks per min) were delivered to their paws for 30 min. Control animals did not receive shocks. Other details are described above. Each bar represents the mean ± SEM of seven animals.
RESULTS AND DISCUSSION
All analogs shown in Table 1 were synthesized by using the solid-phase approach and the Boc strategy with orthogonal protection (Fmoc and Ofm) of the side chains of residues to be cyclized (17) . Best results were obtained when the peptide chain was assembled in its entirety prior to cleavage of the Fmoc and Ofm protecting groups and HBTU-mediated cyclization. The peptides were cleaved and deprotected in HF and purified by reversed-phase HPLC and an assortment of solvent systems (21) . While the synthesis of the different CRF v analogs described in Table 1 did not offer major difficulties, it X should be noted that we have also isolated major components of our synthetic mixtures that presented with the desired masses minus 18. We strongly suspect the formation of an aspartimyl ring to be responsible for loss of one molecule of water (26) . The analytical techniques used for the characterization of the analogs (Table 1) Astressin was found to be 32 times more potent than our o present standard at inhibiting ACTH secretion in vitro, and 100
times more potent than a-helical CRF-(9-41). The corresponding linear analog (compound 5) is 1/300th as potent, suggesting that the Glu30 to Lys33 lactam bridge is essential in 0 constraining the bioactive conformation. It should be noted that while compound 3 is more potent than compound 1, which -_ itself is more potent than compound 5, CD data in aqueous buffer suggest that compound 3 is more helical than compoundn 5, which itself is more helical than compound 1. This apparent lack of correlation between relative potency/binding affinity EH ( Table 1 ) and structure determined by CD cannot be explained at this time, yet it is not without precedent (12, 16) . While receptor/membrane mediated effects are poorly understood at this time, more rigorous structural data obtained by using NMR and possibly x-ray diffraction could suggest more refined and testable hypotheses for our understanding of CRF structure activity relationships.
Interestingly, astressin at the highest doses tested showed less intrinsic activity than either compound 1 or 2 and, therefore, was expected to be more effective in vivo than compound 1 when tested in two in vivo assays. Results of the effects of two low doses of astressin on ACTH secretion in adrenalectomized rats are shown in Fig. 2 . The fact that 30 ,ug and 100 ,ug of astressin per kg administered i.v. still produced a significant decrease in ACTH levels at 45 and 90 min, respectively, was unexpected in view of the lack of a similar effect of 3 mg of compound 1 per kg. A dose of 300 ,ug of astressin per kg was necessary for consistent and complete inhibition at the 90-min time point (data not shown). No significant inhibition was observed at the 120-min time point with any of the doses tested. We also tested the ability of astressin to inhibit stress-induced ACTH release in intact rats. Astressin was at least 10 times more potent than compound 1 in decreasing ACTH levels 10 and 30 min after initiation of the stress (Fig. 3 An antagonist suitable for iodination is essential for future receptor studies; compound 4 was synthesized and found to be less potent than astressin in the rat anterior pituitary cell culture assay. The iodinated analog binds with high affinity, similar to that of astressin, in a membrane receptor assay (Table 1 ) and appears to be an ideal ligand for binding studies (24) . From the data in Table 1 , it is seen that the new cyclic antagonists have affinities for the cloned pituitary receptor that are equal to or greater than 10 times those of the first generations of CRF antagonists and three times that of r/hCRF. The Glu30 to Lys33 lactam bridge was also introduced in compound 7, one of the most potent CRF agonists. The limited 2-fold increase in potency for both the cyclic (compound 8) and the linear (compound 9) analogs raises the possibility that the N terminus of CRF fulfills two independent roles: to activate the receptor and to induce strong a-helicity along the whole CRF molecule. Indeed, the fact that both linear and cyclic peptides are statistically equipotent suggests that the bridge does not contribute significantly to the stabilization of the overall bioactive conformation of the agonist.
hCRF loses its ability to stimulate hypophyseal ACTH release when binding to the CRF-BP (affinity of hCRF for CRF-BP is -10 times greater than that for the CRF receptor) (22) . Therefore, we anticipate that any antagonist with high binding affinity to the CRF-BP may be less efficacious in vivo when CRF-BP is present. We found in a systematic structure activity relationship study that CRF-BP binds hCRF and carp urotensin I with high affinity, sauvagine with moderate affin-
Control
Stress Stress (10 min) (30 ity, and oCRF with low affinity (22) . Among the antagonists reported to date, compound 2 has high affinity for CRF-BP while compound 1 has low affinity. Since residues Asp9-Leu10-Thr" seemed to be important for binding, it was expected that compounds 3-5 would have low affinity for the binding protein, as shown in Table 1 . Accordingly, the agonists (compounds 7-9) have 1/40th the affinity for the CRF-BP as compared with r/hCRF, with the influence of the cycle being insignificant (compare the affinity of compound 7 for CRF-BP with that of 8).
Prior generations of CRF antagonists have been administered at high concentrations in the central nervous system and shown to effectively blunt endogenous CRF actions; however, antagonists that would be potent and long acting on ACTH secretion have been lacking. Astressin is a significant improvement over previously available CRF antagonists due to its high potency, low intrinsic activity, high receptor affinity, and high solubility in neutral aqueous solutions.
Because astressin is effective at low doses, the impact of its limited intrinsic activity at high concentrations in vitro may be of limited consequence in vivo. Also, the availability of a high affinity antagonist radioligand will now allow further advances in receptor pharmacology. These results illustrate the role secondary and tertiary structures may play in controlling biological signaling through protein-ligand interactions. To our knowledge, there is no documented evidence for such long distance induction/stabilization (imparted by residues 4-11) of a-helix formation that can be restored by a single bridging element 20 residues down the sequence upon deletion of these residues. We have shown that a Glu/Lys i-(i + 3) and i-(i + 4) lactam bridge may impart the proper geometry for the stabilization of an a-helical backbone (16) . Additionally, Creamer and Rose (27) have concluded on the basis of changes in configurational entropy of a residue side chain upon transfer from an unfolded state to the an a-helical state that "general factors that drive helix formation must originate in the backbone" (27) . We conclude, therefore, that it is likely that the increased potency of atressin compared with that of compound 5 is due to the added, lactam ring-induced constraints of the backbone that lead to a stabilized a-helix extending the whole length of the fragment in the receptor environment. Finally, because the CRF receptors belong to an extended subfamily of receptors for peptides, including vasoactive intestinal peptide (28) , calcitonin (29) , secretin (30) , parathyroid hormone (31), and growth hormone-releasing factor (32), the possibility remains that these hormones with truncated N termini may be stabilized in a similar manner to that of astressin for the generation of potent antagonists.
